Mercachem logo voor websites

 Mercachen 2 Milestone Almirall

 

In December 2016, Almirall obtained exclusive rights to Mercachem’s cytokine blockers program, such that Mercachem would work to identify and develop novel small-molecule therapeutics for inflammatory skin diseases. With the nomination of a lead compound, Mercachem achieved the second milestone in the medicinal chemistry collaboration program for developing and progressing small-molecule cytokine blockers. Mercachem is also eligible to receive further development milestones.

“This shows the innovative research capabilities of Mercachem to progress challenging targets and chemistries, and also demonstrates the true strength of working in partnerships.” said Eelco Ebbers, co-founder and Managing Director of Mercachem.

 

Full Press Release

Contact Us